NXGLW
NEXGEL, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$0.01
+1.63%Aug 21, 2026, 00:00 UTC
NexGel, Inc. appointed Kevin Harris as Chair of the Special Committee for Strategic Review and Value Creation, effective August 20, 2026.
Aug 20, 2026, 20:05 UTC
NEXGEL, Inc. formed a Special Committee for Strategic Review and Value Creation.
Source:Aug 20, 2026, 20:05 UTC
NEXGEL, Inc. appointed Brian Kieser as Interim Chief Executive Officer.
Source:Aug 17, 2026, 00:00 UTC
NEXGEL, Inc. reported Q2 2026 revenue of $3.69 million and a net loss of $2.87 million.
May 28, 2026, 00:00 UTC
Celularity Inc entered into a settlement agreement with Helena Global Investment Opportunities 1 Ltd to resolve default claims, obligating Celularity to pay $500,000 immediately plus five monthly $100,000 installments and assign a $2.5 million principal promissory note from NEXGEL Inc to Helena, with obligations secured by existing collateral.